Attivatori della glucochinasi: nuovo target per il trattamento del diabete mellito di tipo 2?

Several factors contribute to the development of hyperglycemia in type 2 diabetes mellitus, especially the increase of hepatic gluconeogenesis and the insulin secretion and sensitivity. The glucokinase activators (GKAs) act on these pathogenetic mechanisms by promoting glucose metabolism, representing a new potential class of drugs able to regulate glycemia and enhance β-cell function.
This review reports the current literature about the mechanisms of action of these new-generation GKAs and assess their efficacy and safety in treating T2DM based on preclinical studies and clinical trials.